Pediatric lung transplantation

Seminars in Pediatric Surgery

Volumn 15, Issue 3, 2006, Pages 199-207

  Huddleston, Charles B ^a  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

Cystic fibrosis; Opportunistic infection; Pediatric lung transplantation; Pulmonary vascular disease

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOSPORIN; DACLIZUMAB; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PENTAMIDINE; PREDNISONE; RITUXIMAB; STEROID; SURFACTANT; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; BRONCHIOLITIS OBLITERANS; CYSTIC FIBROSIS; DEATH; DONOR; DONOR SELECTION; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; HEART ARRHYTHMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUNG DYSPLASIA; LUNG FUNCTION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; METABOLISM; MORTALITY; NERVE INJURY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SURGICAL TECHNIQUE; TREATMENT CONTRAINDICATION; VASCULAR DISEASE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; LUNG DISEASES; LUNG TRANSPLANTATION; TREATMENT OUTCOME;

EID: 33745507986     PISSN: 10558586     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2006.03.006     Document Type: Article

References (56)

1. Cooper J.D., Ginsberg R.J., Goldberg M., and the Toronto Lung Transplant Group. Unilateral transplantation for pulmonary fibrosis. N Engl J Med 314 (1986) 1140-1145
2. Boucek M.M., Edwards L.B., Keck B.M., et al. Registry of the International Society for Heart and Lung Transplantation. eighth official pediatric report, 2005. J Heart Lung Transplant 24 (2005) 968-982
3. Cystic Fibrosis Foundation, Patient Registry Annual Report, 2-12 (2004)
4. Kerem E., et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 326 (1992) 1187-1191
5. Mayer-Hamblett N., et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 166 (2002) 1550-1555
6. Moorcroft A.J., Dodd M.E., and Webb A.K. Exercise testing and prognosis in adult cystic fibrosis. Thorax 523 (1997) 291-293
7. Tantisira K.G., Systrom D.M., and Ginns L.C. An elevated breathing reserve index at the lactate threshold is a predictor of mortality in patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 165 (2002) 1629-1633
8. Aurora P., et al. A model for predicting life expectancy of children with cystic fibrosis. Eur Respir J 16 (2000) 1056-1060
9. Vizza C.D., et al. Outcome of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 162 (2000) 819-825
10. Stanchina M.L., et al. Association of lung perfusion disparity and mortality in patients with cystic fibrosis awaiting lung transplantation. J Heart Lung Transplant 21 (2002) 217-225
11. Sharma R., et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 56 (2001) 746-750
12. Rosenbluth D.B., Wilson K., Ferkol T., et al. Lung function decline in cystic fibrosis patients and timing for lung transplantation. Chest 126 (2004) 412-419
13. Rosenzweig E.B., and Barst R. Idiopathic pulmonary arterial hypertension in children. Curr Opin Ped 17 (2005) 372-380
14. Barst R.J., Maislin G., and Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99 (1999) 1197-1208
15. Shapiro S.M., Oudiz R.J., Cao T., et al. Primary pulmonary hypertension. improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30 (1997) 343-349
16. Okano Y., Yoshioka T., Shimouchi A., et al. Orally active prostacyclin analogue in primary pulmonary. Lancet 349 (1997) 1365
17. Barst R.J., McGoon M., McLaughlin V., et al., Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125
18. Olschewski H., Simonneau G., Galie N., et al., Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
19. Barst R.J., Horn E.M., Widlitz A.C., et al. Efficacy of long-term subcutaneous infusion of UT-15 in primary pulmonary hypertension. Eur Heart J 21 (2000) 315
20. Rosenzweig E.B., Ivy D.D., Widlitz A., Doran A., Claussen L.R., Yung D., et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Card 46 (2005) 697-704
21. Sastry B.K., Narasimhan C., Reddy N.K., and Raju B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension. J Am Coll Cardiol 43 (2004) 1149-1153
22. Sandoval J., Gaspar J., Pulido T., et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 32 (1998) 297-304
23. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
24. Clabby M.L., Canter C.E., Moller J.H., and Bridges N.D. Hemodynamic data and survival in children with pulmonary hypertension. J Am Coll Cardiol 30 (1997) 554-560
25. Hopkins W.E., Ochoa L.L., Richardson G.W., and Trulock E.P. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 15 (1996) 100-105
26. Brasch F., and Muller K.M. Classification of pulmonary alveolar proteinosis in newborns, infants, and children. Pathologe 25 (2004) 299-309
27. Shulenin S., et al. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 350 (2004) 1296-1303
28. Tredano M., et al. Mutation of SFTPC in infantile pulmonary alveolar proteinosis with or without fibrosing lung disease. Am J Med Genet 126A (2004) 18-26
29. Majnemer A., et al. Severe bronchopulmonary dysplasia increases risk for later neurological and motor sequelae in preterm survivors. Dev Med Child Neurol 42 (2000) 53-60
30. Serrano-Ikkos E., et al. Incomplete adherence after pediatric heart and heart-lung transplantation. J Heart Lung Transplant 17 (1998) 1177-1183
31. Trulock E.P., Edwards L.B., Taylor D.O., Boucek M.M., Keck B.M., and Hertz M.I. Registry of the International Society for Heart and Lung Transplantation. twenty-second official adult lung and heart-lung transplant report-2005. J Heart Lung Transplant 24 (2005) 956-967
32. Shane E., et al. Bone loss and fracture after lung transplantation. Transplantation 68 (1999) 220-227
33. Ujhelyi R., et al. Bone mineral density and bone acquisition in children and young adults with cystic fibrosis. a follow-up study. J Pediatr Gastroenterol Nutr 38 (2004) 401-406
34. Madill J., et al. Nutritional assessment of the lung transplant patient. body mass index as a predictor of 90-day mortality following transplantation. J Heart Lung Transplant 20 (2001) 288-296
35. Snell G.I., et al. Body mass index as a predictor of survival in adults with cystic fibrosis referred for lung transplantation. J Heart Lung Transplant 17 (1998) 1097-1103
36. Aris R.M., et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 164 (2001) 2102-2106
37. De Soyza A., and Corris P.A. Lung transplantation and the Burkholderia cepacia complex. J Heart Lung Transplant 22 (2003) 954-958
38. Serrano-Ikkos E., Lask B., Whitehead B., and Eisler I. Incomplete adherence after pediatric heart and heart-lung transplantation. J Heart Lung Transplant 17 (1998) 1177-1183
39. Sredl D., Werner T., Springhart D., et al. An evidence-based pilot study exploring relationships between psychologic and physiologic factors in post-lung-transplant adolescents with cystic fibrosis. J Ped Nurs 18 (2003) 216-220
40. Sundaresan S., Semenkovich J., Ochoa L., et al. Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs. J Thorac Cardiovasc Surg 109 (1995) 1075-1079
41. Huddleston C.B., and Mendeloff E.N. Heart and lung preservation for transplantation. J Card Surg 15 (2000) 108-121
42. King R.C., Binns O.A.R., Rodriguz F., et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 69 (2000) 1681-1685
43. Date H., Triantafillou A.N., Trulock E.P., et al. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 111 (1996) 913-919
44. 1. Am Rev Respir Dis 148 (1993) 882-889
45. Metras D., et al. Lung infections in pediatric lung transplantation. experience in 49 cases. Eur J Cardiothorac Surg 15 (1999) 490-494
46. Apalsch A.M., et al. Parainfluenza and influenza virus infections in pediatric organ transplant recipients. Clin Infect Dis 20 (1995) 394-399
47. Bridges N.D., et al. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg 116 (1998) 617-623
48. Sheridan P.H., Cheriyan A., Doud J., et al. Incidence of phrenic neuropathy after isolated lung transplantation. J Heart Lung Transplant 14 (1995) 684-691
49. Huddleston C.B., Sweet S.C., Mallory G.B., et al. Lung transplantation in very young infants. J Thorac Cardiovasc Surg 118 (1999) 796-804
50. Gandhi S.K., Bromberg B.I., Schuessler R.B., et al. Left sided atrial flutter-characterization of a novel complication of pediatric lung transplantation in an acute canine model. J Thorac Cardiovasc Surg 112 (1996) 992-1001
51. Sundaresan S., Trulock E.P., Mohanakumar T., Cooper J.D., and Patterson G.A. Prevalence and outcome of bronchiolitis syndrome after lung transplantation. Ann Thorac Surg 60 (1995) 1341-1346
52. Ganne V., Siddiqi N., Kamaplath B., et al. Humanized anti-CD20 monoclonal antibody (rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 17 (2003) 417-422
53. Swinnen L.J., Mullen G.M., Carr T.J., Costanzo M.R., and Fisher R.I. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86 (1995) 3333-3340
54. Hislop A.A., Odom N.J., McGregor C.G.A., and Haworth S.G. Growth potential of the immature transplanted lung. an experimental study. J Thorac Cardiovasc Surg 100 (1990) 360-370
55. Kern J.A., Tribble C.G., Flanagan T.L., Chan B.B.K., Scott W.W., Cassada D.C., and Kron I.L. Growth potential of porcine reduced-size mature pulmonary lobar transplants. J Thorac Cardiovasc Surg 104 (1992) 1329-1332
56. Cohen A.H., Mallory G.B., Ross K., et al. Growth of lungs after transplantation in infants and in children younger than 3 years of age. Am J Resp Crit Care Med 159 (1999) 1747-1751